Journal article
Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35
CX Qin, LV Norling, EA Vecchio, EP Brennan, LT May, D Wootten, C Godson, M Perretti, RH Ritchie
British Journal of Pharmacology | Published : 2022
DOI: 10.1111/bph.15919
Abstract
We discuss the fascinating pharmacology of formylpeptide receptor 2 (FPR2; often referred to as FPR2/ALX since it binds lipoxin A4). Initially identified as a low-affinity ‘relative’ of FPR1, FPR2 presents complex and diverse biology. For instance, it is activated by several classes of agonists (from peptides to proteins and lipid mediators) and displays diverse expression patterns on myeloid cells as well as epithelial cells and endothelial cells, to name a few. Over the last decade, the pharmacology of FPR2 has progressed from being considered a weak chemotactic receptor to a master-regulator of the resolution of inflammation, the second phase of the acute inflammatory response. We propose..
View full abstractGrants
Awarded by Monash University
Funding Acknowledgements
Medical Research Council, Grant/Award Number: MR/N017544/1; National Heart Foundation of Australia, Grant/Award Numbers: 101857, 102787; Versus Arthritis, Grant/Award Number: 22235; Science Foundation Ireland, Grant/Award Number: SFI/15/US B3130; Bristol-Myers Squibb; Barts Charity, Grant/Award Numbers: MGU0443, MGU0489; National Health and Medical Research Council (NHMRC) of Australia, Grant/Award Numbers: ID1120853, ID1145769, ID1155302, ID1187989